JWCTF (JW (Cayman) Therapeutics Co) Beneish M-Score: -4.34 (As of Jun. 26, 2026)


JWCTF JW (Cayman) Therapeutics Co Ltd JWCTF
30 GF Score
Price $0.24
GF Value $0.57
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is JW (Cayman) Therapeutics Co Beneish M-Score?

JW (Cayman) Therapeutics Co JWCTF 30 Beneish M-Score is -4.34 as of Jun. 26, 2026. GuruFocus rates JWCTF with a GF Score™ of 30/100 and a GF Value™ of $0.57 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 831 Biotechnology companies, JW (Cayman) Therapeutics Co ranks better than 91.34% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -4.34 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for JW (Cayman) Therapeutics Co's Beneish M-Score or its related term are showing as below:

JWCTF' s Beneish M-Score Range Over the Past 10 Years
Min: -4.34   Med: -3.85   Max: 0.92
Current: -4.34

During the past 8 years, the highest Beneish M-Score of JW (Cayman) Therapeutics Co was 0.92. The lowest was -4.34. And the median was -3.85.

JW (Cayman) Therapeutics Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for JW (Cayman) Therapeutics Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JW (Cayman) Therapeutics Co Beneish M-Score Chart

JW (Cayman) Therapeutics Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial 0.00 0.92 -4.22 -3.47 -4.34

JW (Cayman) Therapeutics Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.22 0.00 -3.47 0.00 -4.34

JWCTF vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

JW (Cayman) Therapeutics Co Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where JW (Cayman) Therapeutics Co's Beneish M-Score falls into.


JWCTF
30GF Score
JW (Cayman) Therapeutics Co Ltd JWCTF
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

JW (Cayman) Therapeutics Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of JW (Cayman) Therapeutics Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1+0.528 * 0.8008+0.404 * 0.5838+0.892 * 1.8533+0.115 * 0.8818
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.5593+4.679 * -0.484799-0.327 * 1.4343
=-4.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was $0.32 Mil.
Revenue was $40.27 Mil.
Gross Profit was $24.57 Mil.
Total Current Assets was $80.97 Mil.
Total Assets was $140.12 Mil.
Property, Plant and Equipment(Net PPE) was $30.13 Mil.
Depreciation, Depletion and Amortization(DDA) was $11.63 Mil.
Selling, General, & Admin. Expense(SGA) was $20.67 Mil.
Total Current Liabilities was $56.00 Mil.
Long-Term Debt & Capital Lease Obligation was $5.15 Mil.
Net Income was $-78.84 Mil.
Gross Profit was $0.00 Mil.
Cash Flow from Operations was $-10.91 Mil.
 Total Receivables was $0.00 Mil.
Revenue was $21.73 Mil.
Gross Profit was $10.62 Mil.
Total Current Assets was $111.07 Mil.
Total Assets was $230.80 Mil.
Property, Plant and Equipment(Net PPE) was $37.84 Mil.
Depreciation, Depletion and Amortization(DDA) was $12.32 Mil.
Selling, General, & Admin. Expense(SGA) was $19.94 Mil.
Total Current Liabilities was $63.88 Mil.
Long-Term Debt & Capital Lease Obligation was $6.34 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.316 / 40.273) / (0 / 21.731)
=0.007846 / 0
=1

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(10.619 / 21.731) / (24.574 / 40.273)
=0.488657 / 0.610185
=0.8008

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (80.972 + 30.126) / 140.12) / (1 - (111.071 + 37.843) / 230.797)
=0.207122 / 0.354784
=0.5838

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=40.273 / 21.731
=1.8533

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(12.315 / (12.315 + 37.843)) / (11.625 / (11.625 + 30.126))
=0.245524 / 0.278436
=0.8818

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(20.668 / 40.273) / (19.938 / 21.731)
=0.513197 / 0.917491
=0.5593

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((5.146 + 55.996) / 140.12) / ((6.338 + 63.875) / 230.797)
=0.436355 / 0.30422
=1.4343

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-78.841 - 0 - -10.911) / 140.12
=-0.484799

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

JW (Cayman) Therapeutics Co has a M-score of -4.34 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -4.34 mean?
JW (Cayman) Therapeutics Co (JWCTF) has a Beneish M-Score of -4.34 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on JW (Cayman) Therapeutics Co and its competitors. According to the industry distribution chart, JW (Cayman) Therapeutics Co ranks #72 out of 831 companies in the Biotechnology industry, placing it in the top 8.7%.
Is JW (Cayman) Therapeutics Co's Beneish M-Score too high?
JW (Cayman) Therapeutics Co's current Beneish M-Score is -4.34. Based on the distribution chart, JW (Cayman) Therapeutics Co ranks #72 out of 831 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, JW (Cayman) Therapeutics Co has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does JW (Cayman) Therapeutics Co's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, JW (Cayman) Therapeutics Co ranks #72 out of 831 companies for Beneish M-Score. This places JW (Cayman) Therapeutics Co in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on JW (Cayman) Therapeutics Co and its competitors. JW (Cayman) Therapeutics Co's current Beneish M-Score is -4.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JW (Cayman) Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co (JWCTF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.57, compared to a current price of $0.24 — trading 58.3% below its estimated fair value. The current Beneish M-Score is -4.34. JW (Cayman) Therapeutics Co's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For JW (Cayman) Therapeutics Co (JWCTF), the current Beneish M-Score is -4.34 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is JW (Cayman) Therapeutics Co (JWCTF) Overvalued in 2026?

Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co stock appears to be undervalued. The current stock price of $0.24 is trading 58.3% below its estimated GF Value™ of $0.57. GuruFocus considers JW (Cayman) Therapeutics Co to be Possible Value Trap.

Key valuation signals for JWCTF:

  • Beneish M-Score: -4.34
  • GF Value™: $0.57 vs. price of $0.24 (58.3% below fair value)
  • GF Score™: 30/100 with 3 warning signs

No single metric tells the full story. See the JWCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

JW (Cayman) Therapeutics Co Business Description

Other Exchanges 02126:Hong KongJNY:Germany
Address No. 699 Zhong Ke Road, 5th Floor, Building B, Wison Center, Pudong New District, Shanghai, CHN
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
30GF Score

Get the complete analysis for JWCTF

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.24
Price
$0.57
GF Value